Christopher Boerner S.'s Insider Trades & SAST Disclosures
Christopher Boerner S.'s most recent trade in Bristol-Myers Squibb Co. was a trade of 145,607 Performance Shares done . Disclosure was reported to the exchange on March 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Christopher Boerner S..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 145,607 | 145,607 | - | - | Performance Shares | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 97,071 | 97,071 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 39,700 | 152,898 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 39,700 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 14,641 | 138,257 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 12,818 | 125,439 (0%) | 0% | 63.1 | 808,944 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 6,985 | 111,611 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 6,985 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 6,733 | 13,466 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 6,733 | 117,203 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 6,616 | 114,418 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 6,616 | 6,618 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 3,327 | 107,802 (0%) | 0% | 63.1 | 209,967 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 2,858 | 113,198 (0%) | 0% | 63.1 | 180,368 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 2,794 | 110,470 (0%) | 0% | 63.1 | 176,329 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 1,154 | 113,264 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 1,147 | 116,056 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 482 | 111,129 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 55.05 per share. | 20 Feb 2025 | 2,000 | 104,626 (0%) | 0% | 55.0 | 110,096 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 2,964 | 104,169 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 2,964 | 8,894 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 54.32 per share. | 01 Nov 2024 | 1,488 | 102,626 (0%) | 0% | 54.3 | 80,828 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 01 Nov 2024 | 55 | 104,114 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 148,026 | 148,026 | - | - | Performance Shares | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 98,684 | 98,684 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 41,910 | 129,769 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 41,910 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 14,589 | 115,180 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 13,975 | 101,205 (0%) | 0% | 53.8 | 751,715 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 6,985 | 92,020 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 6,985 | 6,985 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 6,733 | 20,199 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 6,616 | 13,234 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 5,743 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 5,743 | 88,415 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 2,957 | 87,859 (0%) | 0% | 53.8 | 159,057 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 2,475 | 85,035 (0%) | 0% | 53.8 | 133,130 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 1,204 | 90,816 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 905 | 87,510 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Boerner Christopher S. | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 49.78 per share. | 05 Dec 2023 | 2,000 | 82,672 (0%) | 0% | 49.8 | 99,560 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Boerner S. Christopher | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2023 | 2,638 | 0 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb Co. | Christopher Boerner S. | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2023 | 2,638 | 82,022 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Boerner S. Christopher | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.10 per share. | 02 Dec 2023 | 1,350 | 80,672 (0%) | 0% | 50.1 | 67,635 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 48.86 per share. | 28 Nov 2023 | 3,071 | 79,384 (0%) | 0% | 48.9 | 150,049 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2023 | 17,788 | 17,788 | - | - | Performance Shares | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2023 | 11,858 | 11,858 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 40,398 | 40,398 | - | - | Performance Shares | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 34,450 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 34,450 | 91,880 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 26,932 | 26,932 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 19,773 | 76,313 (0%) | 0% | 65.7 | 1,299,284 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 6,985 | 13,970 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 6,985 | 57,108 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 6,616 | 19,850 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 6,616 | 60,710 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 5,741 | 52,541 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 5,741 | 5,743 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 5,319 | 48,573 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 5,319 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 4,206 | 96,086 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 4,160 | 54,094 (0%) | 0% | 65.7 | 273,354 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 3,713 | 46,800 (0%) | 0% | 65.7 | 243,981 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 3,494 | 57,430 (0%) | 0% | 65.7 | 229,591 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 3,480 | 50,123 (0%) | 0% | 65.7 | 228,671 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 1,940 | 50,513 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 1,146 | 58,254 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 1,062 | 53,603 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 214 | 60,924 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 2,637 | 2,638 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 2,637 | 44,603 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.13 per share. | 02 Dec 2022 | 1,349 | 43,254 (0%) | 0% | 81.1 | 109,444 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 69.20 per share. | 14 Mar 2022 | 29,532 | 41,966 (0%) | 0% | 69.2 | 2,043,526 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 39,700 | 39,700 | - | - | Performance Shares | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 31,909 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 31,909 | 81,649 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 26,466 | 26,466 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 22,784 | 71,498 (0%) | 0% | 68.4 | 1,558,881 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 12,633 | 94,282 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 6,985 | 20,955 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 6,985 | 52,930 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 5,741 | 11,484 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 5,741 | 48,512 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 5,318 | 5,319 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 5,318 | 44,702 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 3,974 | 49,740 (0%) | 0% | 68.4 | 271,901 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 3,547 | 42,771 (0%) | 0% | 68.4 | 242,686 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 3,325 | 45,945 (0%) | 0% | 68.4 | 227,497 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 1,762 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 1,762 | 40,274 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2022 | 1,616 | 46,318 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 915 | 39,384 (0%) | 0% | 68.4 | 62,604 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 784 | 53,714 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2022 | 758 | 49,270 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2022 | 25 | 40,299 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2021 | 2,638 | 5,275 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2021 | 2,638 | 39,862 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.41 per share. | 02 Dec 2021 | 1,350 | 38,512 (0%) | 0% | 55.4 | 74,804 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 41,910 | 41,910 | - | - | Performance Shares | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 27,940 | 27,940 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 10,568 | 41,325 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Christopher S. Boerner | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 10,568 | 0 | - | - | Performance Shares |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges